Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890950 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
A Phase 1 study of Obesity and Type 2 Diabetes Mellitus in Obese, sponsored by Kallyope.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05890950: Completed Phase 1 study of Obesity and Type 2 Diabetes Mellitus in Obese, sponsored by Kallyope.
NCT05890950 is a Phase 1 study of Obesity and Type 2 Diabetes Mellitus in Obese that has completed, run by Kallyope. The registered enrollment target is 24 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05890950, a Phase 1 study of Obesity and Type 2 Diabetes Mellitus in Obese, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
Conditions Studied
Interventions
- DRUG K-757 and K-833
- DRUG Matching placebo to K-757 and K-833
Study Locations (1)
Delaware
- QPS, LLC - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2023-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05890950
The ClinicalTrials.gov registry entry for NCT05890950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which K-757 and K-833 is the first listed.
NCT05890950 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT05890950 about?
NCT05890950 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes". This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT05890950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-03-13. Estimated completion is 2023-07-12.
What conditions does trial NCT05890950 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes Mellitus in Obese.
What interventions are being tested in trial NCT05890950?
The interventions under investigation include: K-757 and K-833 (DRUG), Matching placebo to K-757 and K-833 (DRUG).
Who is sponsoring clinical trial NCT05890950?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05890950 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.